Liquidity risks and cannabis sales declines weigh on Tilray stock as seller pressure dominates

Traders Union
All News
Stocks
Tilray drops 4.73% today to $3.12

Highlights

Tilray Brands secured regulatory approval from INFARMED in Portugal to conduct in-house quality testing at its Cantanhede facility, aiming to improve control and support exports.
Quarterly results show rising total revenue from the BrewDog acquisition, but cannabis revenue declined and the company reported continuing net losses and negative free cash flow.
Shares of Tilray trade below key moving averages under sustained selling pressure, with indicators confirming a bearish trend and a high probability of further downside into the $2.94 to $3.3 range.

Quality control gains offset by revenue mix shift and liquidity risks

Tilray Brands received regulatory approval from Portugal's National Authority of Medicines and Health Products (INFARMED) to perform microbiological and chemical/physical quality testing in-house at its Cantanhede facility, a move that supports tighter quality control and may streamline international medical cannabis exports, according to Investing.com. However, first-quarter results indicated that while overall revenue grew due to the BrewDog acquisition, cannabis revenue declined, and Tilray continued to report net losses and negative free cash flow, as noted by Seeking Alpha. In addition, an external review cited by Tipranks warned of possible restrictions on Tilray's access to its revolving credit facility due to stricter covenant terms, elevating liquidity risk and constraining near-term financial flexibility.

Bearish momentum persists as oversold signals and resistance converge

TLRY is trading below the MA-20 at $3.3, MA-50 at $3.51, and long-term MA-200 at $5.89. The Ichimoku Kijun level at $3.38 marks immediate resistance, while current price action is close to session lows. Momentum indicators, including MACD and ADX, continue to show a bearish setup. RSI, Stoch RSI, and CCI all indicate oversold conditions, and Bull/Bear Power signals strong seller dominance. The Awesome Oscillator confirms the ongoing downtrend.

Consolidation likely as breakout risks remain asymmetric

Over the next two to three trading days, TLRY is expected to trade within a typical volatility band between $2.94 and $3.3. The likelihood of an upward breakout is very low, while further downside risk remains elevated. The most probable scenario is price consolidation within this range, unless a decisive break below support accelerates the declining trend or a move above resistance triggers a short-term rebound.

Anton Kharitonov, expert at Traders Union, notes that Tilray faces persistent technical and fundamental headwinds. The stock remains stuck below key moving averages, with momentum and sentiment metrics confirming seller control. Fundamental risks — including declining cannabis revenue, net losses, and liquidity concerns — overshadow regulatory positives. "Until TLRY reclaims key resistance and demonstrates financial improvement, the outlook stays defensive with elevated downside risk."

Previously it was reported that Tilray faced persistent downside pressure as technical weakness and declining cannabis sales overshadowed gains from strategic acquisitions. The current analysis reinforces this view with additional concerns over tightened credit conditions and liquidity risk, making sustained support near the lower end of the projected trading range a critical level to monitor in the days ahead.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.